MDM2 and CDKN1A gene polymorphisms and risk of Kaposi's sarcoma in African and Caucasian patients

Maria Lina Tornesello, Luigi Buonaguro, Medea Cristillo, Bennon Biryahwaho, Robert Downing, Angelo Hatzakis, Elvio Alessi, Marco Cusini, Vincenzo Ruocco, Enza Viviano, Nino Romano, Edward Katongole-Mbidde, Franco M. Buonaguro

Research output: Contribution to journalArticlepeer-review

Abstract

A single-nucleotide polymorphism in the MDM2 promoter (SNP309; rs2279744) causes elevated transcription of this major negative regulator of p53 in several cancer types. We investigated MDM2 SNP309 and CDKN1A (p21/Waf1/Cip1) codon 31 (rs1801270) polymorphisms in 86 cases of cutaneous Kaposi's sarcoma (KS) from African and Caucasian patients, and 210 healthy controls. A significant increase of the MDM2 SNP309 T/G genotype was observed among classic KS cases (odds ratio 2.38, 95% confidence interval 1.0-5.5). Frequencies of CDKN1A codon 31 genotypes were not significantly different between cases and controls. The results suggest that the MDM2 SNP309 G allele may act as a susceptibility gene for the development of classic KS in Caucasian patients.

Original languageEnglish
Pages (from-to)42-50
Number of pages9
JournalBiomarkers
Volume16
Issue number1
DOIs
Publication statusPublished - Feb 2011

Keywords

  • CDKN1A
  • Genetic polymorphisms
  • Kaposi's sarcoma.
  • MDM2

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Health, Toxicology and Mutagenesis

Fingerprint Dive into the research topics of 'MDM2 and CDKN1A gene polymorphisms and risk of Kaposi's sarcoma in African and Caucasian patients'. Together they form a unique fingerprint.

Cite this